Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O94906

UPID:
PRP6_HUMAN

ALTERNATIVE NAMES:
Androgen receptor N-terminal domain-transactivating protein 1; PRP6 homolog; U5 snRNP-associated 102 kDa protein

ALTERNATIVE UPACC:
O94906; B2RAR5; B3KMC6; O95109; Q5VXS5; Q9H3Z1; Q9H4T9; Q9H4U8; Q9NTE6

BACKGROUND:
The protein Pre-mRNA-processing factor 6, known alternatively as PRP6 homolog and U5 snRNP-associated 102 kDa protein, is integral to the spliceosome's function in pre-mRNA splicing. Its involvement in enhancing the transactivation activity of AR and NR3C1 underlines its pivotal role in cellular processes and gene expression.

THERAPEUTIC SIGNIFICANCE:
Linked to the development of Retinitis pigmentosa 60, Pre-mRNA-processing factor 6's dysfunction highlights its potential as a therapeutic target. Understanding the role of Pre-mRNA-processing factor 6 could open doors to potential therapeutic strategies, offering hope for advancements in treatment.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.